MET and bone sarcoma: Both MET and Src have been suggested their involvement in invasion and metastasis process in sarcomas 25, 26, and MET inhibitor, crizotinib, and Src inhibitor, dasatinib showed inhibitory effects for tumor growth, invasion, and metastasis in bone sarcomas both in vitro and in vivo27, 28.